Rovin, Brad H.Martins, ElsaAustin, Cary D.Raghu, HariniChan, CalebChang, PatrickAlberton, ValeriaSantiago, MittermayerAroca-Martinez, GustavoAlfaro, JoseFurie, Richard A.Larson, ChristopherYoo, BonginPendergraft, William F.Malvar, Ana2026-04-062026-04-06202624680249 (Electrónico)https://hdl.handle.net/20.500.12442/17494The REGENCY trial (NCT04221477) demonstrated superiority of obinutuzumab (OBI) plus standard therapy (+ST) vs placebo (PBO) +ST in achieving complete renal response (CRR) at Week 76 (W76) in adults with active lupus nephritis (LN). It was postulated that OBI+ST would yield greater rates of histologic remission and kidney tissue-level B-cell depletion at W76 than PBO+ST, which would portend more favorable long-term kidney outcomes, such as reduced LN flare risk and preserved kidney function. These exploratory analyses aimed to evaluate histologic remission and kidney tissue-level B-cell depletion at W76 in patients treated with OBI+ST vs PBO+ST.pdfengAttribution-NonCommercial-NoDerivatives 4.0 Internationalinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://doi.org/10.1016/j.ekir.2026.106200https://www.kireports.org/article/S2468-0249(26)02431-9/fulltextLupus nephritisB lymphocytes